Neuroleptic malignant syndrome: A review from a clinically oriented perspective

Current Neuropharmacology

Volumn 13, Issue 3, 2015, Pages 395-406

  Tse, Lurdes ^a   Barr, Alasdair M ^a,b   Scarapicchia, Vanessa ^a,b   Vila Rodriguez, Fidel ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Mental Health and Addictions Research Institute   (Canada)

Author keywords

Antipsychotic; Drug side effects; Neuroleptic malignant syndrome; Psychopharmacology

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ARIPIPRAZOLE; ASENAPINE; BIPERIDEN; BROMOCRIPTINE; CHLORPROMAZINE; CLOZAPINE; CREATININE; DANTROLENE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LEVOMEPROMAZINE; LISURIDE; LORAZEPAM; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PAROXETINE; PERICIAZINE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; SERTRALINE; TRIFLUOPERAZINE; TROPONIN; UNINDEXED DRUG; ZIPRASIDONE; ZUCLOPENTHIXOL;

AGE; CANADA; CATATONIA; CEREBROSPINAL FLUID ANALYSIS; CHANNELOPATHY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DEHYDRATION; DOPAMINERGIC TRANSMISSION; DRUG SURVEILLANCE PROGRAM; ELECTROCONVULSIVE THERAPY; ELECTROLYTE BALANCE; ENVIRONMENTAL FACTOR; ENVIRONMENTAL TEMPERATURE; EXERCISE; FAMILY HISTORY; GENETIC SUSCEPTIBILITY; HUMAN; LIVER FUNCTION TEST; MUSCLE ATROPHY; NEUROIMAGING; NEUROLEPTIC MALIGNANT SYNDROME; POLYPHARMACY; PSYCHOSIS; REVIEW; RISK FACTOR; UREA NITROGEN BLOOD LEVEL; URINALYSIS; ANIMAL; COMPLICATION; DIFFERENTIAL DIAGNOSIS; INCIDENCE; MUSCLE RIGIDITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; INCIDENCE; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; RISK FACTORS;

EID: 84938699073     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X13999150424113345     Document Type: Review

References (74)

1. [1] Delay, J, Pichot, P, Lemperiere, T, Elissalde, B, Peigne, F. A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses. Ann. Med. Psychol., (Paris), 1960, 118(1), 145-152.
2. [2] Neppe, V.M. The neuroleptic malignant syndrome. A priority system. South Afr. Med. J., 1984, 65(13), 523-525.
3. [3] Gurrera, R.J, Simpson, J.C, Tsuang, M.T. Meta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidence. Compr. Psychiatry, 2007, 48(2), 205-211. http://dx.doi. org/10.1016/j.comppsych.2006.10.004
4. [4] Pope, H.G., Jr, Keck, P.E., Jr, McElroy, S.L. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am. J. Psychiatry, 1986, 145(10), 1227-1233. http://dx.doi.org/10.1176/ajp.143.10.1227
5. [5] American. Diagnostic and Statistical Manual of Mental Disorders -Fifth Edition. American Psychiatric Publishing: Arlington, VA., 2013.
6. [6] Keck, P.E., Jr, Pope, H.G., Jr, Mcelroy, S.L. Frequency and presentation of neuroleptic malignant syndrome: a prospective study. Am. J. Psychiatry, 1987, 144(10), 1344-1346. http://dx.doi.org/10.1176/ajp.144.10.1344
7. [7] Gelenberg, A.J, Bellinghausen, B, Wojcik, J.D, Falk, W.E, Sachs, G.S. A prospective survey of neuroleptic malignant syndrome in a short-term psychiatric hospital. Am. J. Psychiatry, 1988, 145(4), 517-518. http://dx.doi.org/10.1176/ajp.145.4.517
8. [8] Keck, P.E., Jr, Sebastianelli, J, Pope, H.G., Jr, Mcelroy, S.L. Frequency and presentation of neuroleptic malignant syndrome in a state psychiatric hospital. J. Clin. Psychiatry, 1989, 50(9), 352-355.
9. [9] Deng, M.Z, Chen, G.Q, Phillips, M.R. Neuroleptic malignant syndrome in 12 of 9,792 Chinese inpatients exposed to neuroleptics: a prospective study. Am. J. Psychiatry, 1990, 147(9), 1149-1155. http://dx.doi.org/10.1176/ajp.147.9.1149
10. [10] Spivak, B, Maline, D.I, Kozyrev, V.N, Mester, R, Neduva, S.A, Ravilov, R.S, Weizman, A. Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow. Eur. Psychiatry, 2000, 15(5): 330-333. http://dx.doi.org/10.1016/S0924-9338(00)00402-8
11. [11] Keck, P.E., Jr, Pope, H.G., Jr, McElroy, S.L. Declining frequency of neuroleptic malignant syndrome in a hospital population. Am. J. Psychiatry, 1991, 148(7), 880-882. http://dx.doi.org/10.1176/ajp.148.7.880
12. [12] Sachdev, P, Kruk, J, Kneebone, M, Kissane, D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J. Clin. Psychopharmacol., 1995, 15(5), 365-371. http://dx.doi.org/10.1097/00004714-199510000-00010
13. [13] Anonymous Health Canada: Canada Vigilance Adverse Reaction Online Database. In; Vol. Dec 10 2012.
14. [14] Trollor, J.N, Chen, X, Chitty, K, Sachdev, P.S. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br. J. Psychiatry, 2012, 201(1), 52-56. http://dx.doi.org/10.1192/bjp.bp.111.105189
15. [15] Novartis. Association of CLOZARIL (clozapine) with cardiovascular toxicity [Dear Healthcare Professional Letter]. In; 2002.
16. [16] Procyshyn, R.M, Honer, W.G, Wu, T.K, Ko, R.W, McIsaac, S.A, Young, A.H, Johnson, J.L, Barr, A.M. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J. Clin. Psychiatry, 2010, 71(5), 566-573. http://dx.doi.org/10.4088/JCP.08m04912gre
17. [17] Procyshyn, R.M, Su, J, Elbe, D, Liu, A.Y, Panenka, W.J, Davidson, J, Honer, W.G, Barr, A.M. Prevalence and patterns of antipsychotic use in youth at the time of admission and discharge from an inpatient psychiatric facility. J. Clin. Psychopharmacol., 2014, 34(1), 17-22. http://dx.doi.org/10.1097/JCP.0b013e3182a607dd
18. [18] Argyriou, A.A, Drakoulogona, O, Karanasios, P, Kouliasa, L, Leonidou, L, Giannakopoulou, F, Goudas, P, Makris, N. Lithium-induced fatal neuroleptic malignant syndrome in a patient not being concomitantly treated with commonly offending agents. J. Pain Symptom Manage, 2012, 44(6), e4-6. http://dx.doi.org/10.1016/j.jpainsymman.2012.08.010
19. [19] Edokpolo, O, Fyyaz, M. Lithium toxicity and neurologic effects: probable neuroleptic malignant syndrome resulting from lithium toxicity. Case Rep. Psychiatry, 2012, 2012, 271-858.
20. [20] Sharma, B, Sannegowda, R.B, Gandhi, P, Dubey, P, Panagariya, A. Combination of Steven-Johnson syndrome and neuroleptic malignant syndrome following carbamazepine therapy: a rare occurrence. BMJ Case Rep., 2013, 2013.
21. [21] Uguz, F, Sonmez, E.O. Neuroleptic malignant syndrome following combination of sertraline and paroxetine: a case report. Gen. Hosp. Psychiatry, 2013, 35(3), e327-e328.
22. [22] Janati, A.B, Alghasab, N, Osman, A. Neuroleptic malignant syndrome caused by a combination of carbamazepine and amitriptyline. Case Rep. Neurol. Med., 2012, 2012, 183-252.
23. [23] Friedman, L.S, Weinrauch, L.A, Delia, J.A. Metoclopramide-induced neuroleptic malignant syndrome. Arch. Intern. Med., 1987, 147(8), 1495-1497. http://dx.doi.org/10.1001/archinte.1987.00370080133023
24. [24] Ananth, J, Parameswaran, S, Gunatilake, S, Burgoyne, K, Sidhom, T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J. Clin. Psychiatry, 2004, 65(4), 464-470. http://dx.doi.org/10.4088/JCP.v65n0403
25. [25] Su, Y.P, Chang, C.K, Hayes, R.D, Harrison, S, Lee, W, Broadbent, M, Taylor, D, Stewart, R. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr. Scand., 2013, 130(1), 52-60. http://dx.doi.org/10.1111/acps.12222
26. [26] Meltzer, H.Y, Li, Z, Kaneda, Y, Ichikawa, J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 2003, 27(7), 1159-1172. http://dx.doi.org/10.1016/j.pnpbp.2003.09.010
27. [27] Su, Y.P, Chang, C.K, Hayes, R.D, Harrison, S, Lee, W, Broadbent, M, Taylor, D, Stewart, R. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand, 2013.
28. [28] Viejo, L.F, Morales, V, Punal, P, Perez, J.L, Sancho, R.A. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatr Scand, 2003, 107(1), 45-49. http://dx.doi.org/10.1034/j.1600-0447.2003.02385.x
29. [29] Caroff, S.N, Mann, S.C. Neuroleptic malignant syndrome. Med Clin. North Am., 1993, 77(1), 185-202.
30. [30] Otani, K, Horiuchi, M, Kondo, T, Kaneko, S, Fukushima, Y. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br. J. Psychiatry, 1991, 158, 850-853. http://dx.doi.org/10.1192/bjp.158.6.850
31. [31] Kawanishi, C. Genetic predisposition to neuroleptic malignant syndrome implications for antipsychotic therapy. Am. J. Pharmacogenom., 2003, 3(2), 89-95. http://dx.doi.org/10.2165/00129785-200303020-00002
32. [32] Anglin, R.E, Rosebush, P.I, Mazurek, M.F. Neuroleptic malignant syndrome: a neuroimmunologic hypothesis. CMAJ, 2010, 182(18), E834-838. http://dx.doi.org/10.1503/cmaj.091442
33. [33] Cox, B, Kerwin, R, Lee, T.F. Dopamine receptors in the central thermoregulatory pathways of the rat. J. Physiol., 1978, 282, 471483. http://dx.doi.org/10.1113/jphysiol.1978.sp012476
34. [34] Henderson, V.W, Wooten, G.F. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade? Neurology, 1981, 31(2), 132-137. http://dx.doi.org/10.1212/WNL.3L2.132
35. [35] Stotz, M, Thummler, D, Schurch, M, Renggli, J.C, Urwyler, A, Pargger, H. Fulminant neuroleptic malignant syndrome after perioperative withdrawal of antiParkinsonian medication. Br. J. Anaesth., 2004, 93(6), 868-871. http://dx.doi.org/10.1093/bja/aeh269
36. [36] Haggerty, J.J., Jr, Bentsen, B.S, Gillette, G.M. Neuroleptic malignant syndrome superimposed on tardive dyskinesia. Br. J. Psychiatry, 1987, 150, 104-105. http://dx.doi.org/10.1192/bjp.150.1.104
37. [37] Ossowska, K. Neuronal basis of neuroleptic-induced extrapyramidal side effects. Pol. J. Pharmacol., 2002, 54(4), 299-312.
38. [38] Hermesh, H, Shiloh, R, Epstein, Y, Manaim, H, Weizman, A, Munitz, H. Heat intolerance in patients with chronic schizophrenia maintained with antipsychotic drugs. Am. J. Psychiatry, 2000, 157(8), 1327-1329. http://dx.doi.org/10.1176/appi.ajp.157.8.1327
39. [39] Araki, M, Takagi, A, Higuchi, I, Sugita, H. Neuroleptic malignant syndrome: caffeine contracture of single muscle fibers and muscle pathology. Neurology, 1988, 38(2), 297-301. http://dx.doi.org/10.1212/WNL.38.2.297
40. [40] Gurrera, R.J. Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia? Clin. Neuropharmacol., 2002, 25(4), 183-193. http://dx.doi.org/10.1097/00002826-200207000-00001
41. [41] Chamberlain, B.K, Volpe, P, Fleischer, S. Inhibition of calcium-induced calcium release from purified cardiac sarcoplasmic reticulum vesicles. J. Biol. Chem., 1984, 259(12), 7547-7553.
42. [42] Denborough, M.A, Collins, S.P, Hopkinson, K.C. Rhabdomyolysis and malignant hyperpyrexia. Br. Med. J. (Clin. Res. Ed.), 1984, 288(6434), 1878. http://dx.doi.org/10.1136/bmj.288.6434.1878
43. [43] Wagner, R, Fink, R.H, Stephenson, D.G. Effects of chlorpromazine on excitation-contraction coupling events in fast-twitch skeletal muscle fibres of the rat. Br. J. Pharmacol., 2004, 141(4), 624-633. http://dx.doi.org/10.1038/sj.bjp.0705655
44. [44] Berardi, D, Amore, M, Keck, P.E., Jr, Troia, M, Dellatti, M. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol. Psychiatry, 1998, 44(8), 748-754. http://dx.doi.org/10.1016/S0006-3223(97)00530-1
45. [45] Gruber, M.P. Diagnosing neuroleptic malignant syndrome. Chest, 2004, 125(5), 1960-1961; author reply 1961.
46. [46] Atbasoglu, E.C, Ozguven, H.D, Can Saka, M, Goker, C. Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome. J. Clin. Psychiatry, 2004, 65(12), 1724-1725. http://dx.doi.org/10.4088/JCP.v65n1219f
47. [47] Gambassi, G, Capurso, S, Tarsitani, P, Liperoti, R, Bernabei, R. Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine. Aging Clin. Exp. Res., 2006, 18(3), 266-270. http://dx.doi.org/10.1007/BF03324659
48. [48] Yamawaki, Y, Ogawa, N. Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease. Intern. Med., 1992, 31(11), 1298-1302. http://dx.doi.org/10.2169/internalmedicine.31.1298
49. [49] Oomura, M, Terai, T, Sueyoshi, K, Shigeno, K. Reversible cardiomyopathy as the autonomic involvement of neuroleptic malignant syndrome. Intern. Med., 2004, 43(12), 1162-1165. http://dx.doi.org/10.2169/internalmedicine.43.1162
50. [50] Levenson, J.L. Neuroleptic malignant syndrome. Am. J. Psychiatry, 1985, 142(10), 1137-1145. http://dx.doi.org/10.1176/ajp.142.10.1137
51. [51] Addonizio, G, Susman, V.L, Roth, S.D. Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol. Psychiatry, 1987, 22(8), 1004-1020. http://dx.doi.org/10.1016/0006-3223(87) 90010-2
52. [52] Adityanjee; Aderibigbe, Y.A, Mathews, T. Epidemiology of neuroleptic malignant syndrome. Clin. Neuropharmacol., 1999, 22(3), 151-158.
53. [53] Lazarus, A, Mann, S.C, Caroff, S.N. The neuroleptic malignant syndrome and related conditions. American Psychiatric Press: Washington, D.C., 1988.
54. [54] Spalding, S, Alessi, N.E, Radwan, K. Aripiprazole and atypical neuroleptic malignant syndrome. J. Am. Acad. Child Adolesc. Psychiatry, 2004, 43(12), 1457-1458. http://dx.doi.org/10.1097/01.chi.0000142277.95052.94
55. [55] Duggal, H.S. Possible neuroleptic malignant syndrome associated with paliperidone. J. Neuropsychiatry Clin. Neurosci, 2007, 19(4), 477-478. http://dx.doi.org/10.1176/jnp.2007.19.4.477
56. [56] Picard, L.S, Lindsay, S, Strawn, J.R, Kaneria, R.M, Patel, N.C, Keck, P.E., Jr. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy, 2008, 28(4), 530-535. http://dx.doi.org/10.1592/phco.28.4.530
57. [57] Boyda, H.N, Procyshyn, R.M, Tse, L, Wong, D, Pang, C.C, Honer, W.G, Barr, A.M. Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacology, 2012, 62(3), 1391-1400. http://dx.doi.org/10.1016/j.neuropharm.2011.02.019
58. [58] Boyda, H.N, Tse, L, Procyshyn, R.M, Wong, D, Wu, T, K Pang, C.C Barr, A.M. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 54(6), 945-954. http://dx.doi.org/10.1016/j.pnpbp.2010.04.024
59. [59] Leung, J.Y, Barr, A.M, Procyshyn, R.M, Honer, W.G, Pang, C.C. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol. Ther., 2012, 155(2), 113-122. http://dx.doi.org/10.1016Zi.pharmthera.2012.04.003
60. [60] Dunkley, E.J, Isbister, G.K, Sibbritt, D, Dawson, A.H, Whyte, I.M. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM, 2003, 96(9), 635-642. http://dx.doi.org/10.1093/qjmed/hcg109
61. [61] Kontaxakis, V.P, Havaki-Kontaxaki, B.J, Christodoulou, N.G, Paplos, K.G, Christodoulou, G.N. Olanzapine-associated neuroleptic malignant syndrome: Is there an overlap with the serotonin syndrome? Ann. Gen. Hosp. Psychiatry, 2003, 2(1), 10. http://dx.doi.org/10.1186/1475-2832-2-10
62. [62] Stevens, D.L. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. Ann. Pharmacother., 2008, 42(9), 1290-1297. http://dx.doi.org/10.1345/aph.1L066
63. [63] Birmes, P, Coppin, D, Schmitt, L, Lauque, D. Serotonin syndrome: a brief review. CMAJ, 2003, 168(11), 1439-1442.
64. [64] Kaufman, K.R, Levitt, M.J, Schiltz, J.F, Sunderram, J. Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting: case analysis. Ann. Clin. Psychiatry, 2006, 18(3), 201-204. http://dx.doi.org/10.1080/10401230600801259
65. [65] Lappin, R.I, Auchincloss, E.L. Treatment of the serotonin syndrome with cyproheptadine. N. Engl. J. Med., 1994, 331(15), 1021-1022. http://dx.doi.org/10.1056/NEJM199410133311514
66. [66] Montanes-Rada, F, Bilbao-Garay, J, de Lucas-Taracena, M.T, Ortiz-Ortiz, M.E. Venlafaxine, serotonin syndrome, and differential diagnoses. J. Clin. Psychopharmacol., 2005, 25(1), 101-102. http://dx.doi.org/10.1097/01.jcp.0000150236.45361.e1
67. [67] Taylor, M.A, Fink, M. Catatonia in psychiatric classification: a home of its own. Am. J. Psychiatry, 2003, 160(7), 1233-1241. http://dx.doi.org/10.1176/appi.ajp.160.7.1233
68. [68] Collard, H.R, Saint, S, Matthay, M.A. Prevention of ventilator-associated pneumonia: an evidence-based systematic review. Ann Intern Med., 2003, 138(6), 494-501. http://dx.doi.org/10.7326/ 0003-4819-138-6-200303180-00015
69. [69] Pelonero, A.L, Levenson, J.L, Pandurangi, A.K. Neuroleptic malignant syndrome: a review. Psychiatr. Serv., 1998, 49(9), 1163-1172. http://dx.doi.org/10.1176/ps.49.9.1163
70. [70] Rosebush, P.I, Stewart, T, Mazurek, M.F. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br. J. Psychiatry, 1991, 159, 709-712. http://dx.doi.org/10.1192/bjp.159.5.709
71. [71] Rosenberg, M.R, Green, M. Neuroleptic malignant syndrome. Review of response to therapy. Arch. Intern. Med., 1989, 149(9), 1927-1931. http://dx.doi.org/10.1001/archinte.1989.00390090009002
72. [72] Scheftner, W.A, Shulman, R.B. Treatment Choice in Neuroleptic Malignant Syndrome. Convuls Ther., 1992, 8(4), 267-279.
73. [73] Mahendran, R, Winslow, M, Lim, D. Recurrent neuroleptic malignant syndrome. Aust N Z J Psychiatry, 2000, 34(4), 699-700. http://dx.doi.org/10.1080/j.1440-1614.2000.0766g.x
74. [74] Shalev, A, Hermesh, H, Munitz, H. Mortality from neuroleptic malignant syndrome. J. Clin. Psychiatry, 1989, 50(1), 18-25.